Newer antiviral drugs, such as Mark and Pfizer pills, are mostly for people with mild to moderate symptoms, so new treatment is urgently needed for critically ill Kovid-19 patients.
Sabizabulin, a new drug that has been clinically tested in the United States and other countries (Brazil, Argentina, Mexico, Colombia and Bulgaria), has significantly reduced the mortality rate of Covid-19 patients in severe cases by at least half. (55 percent) who were taking extra oxygen and were at high risk for severe pneumonia, acute respiratory distress syndrome (ARDS) and death.
The double-blind, randomized, placebo-controlled multicenter clinical trial (Phase 3) closed prematurely for a total of 150 patients, according to biopharmaceutical company Veru, whose stock “rose” after being announced on the US Stock Exchange. Induced results. According to the New York Times, no detailed research of these results has been done yet.
Newer antiviral drugs, such as Mark and Pfizer pills, are primarily for people with mild to moderate symptoms, so new treatment is urgently needed for critically ill Covid-19 patients.
In clinical trials of new drugs, of 52 patients About half (45 percent) of those who received a placebo with standard treatment died within the next 60 days, while of the 98 people who also received sabizabulin, only 20 percent died during the same period. The study involved patients with both Delta and Omicron, and the drug appears to be equally effective.
The drug, which is administered once a day (Dosage 9 mg), Does not need to be refrigerated and is currently intended for patients only. It “works” by preventing the coronavirus from going to different places inside the human cell. At the same time, it “slows down” the body’s excessive response to cytokines and therefore excessive inflammation. During the clinical trial of the drug, Veru said, no safety issues were found. The drug was well tolerated by patients.
Dr. Mitchell Steiner, CEO of Veru, said, “Sabizabulin is the first drug to reduce the mortality of moderate to severe COVID-19 among clinically- and statistically significant hospitalized patients,” adding: “We strongly believe that Sabizabulin Due to the dual anti-viral and anti-inflammatory properties that have shown positive efficacy and safety results in the third phase of COVID-19 studies, oral therapy may be very necessary for moderate to severe COVID-19 patients hospitalized. “
In January, the US Food and Drug Administration (FDA) issued an emergency drug license. The agency now wants to seek FDA permission to release it as soon as possible. Veru is already working to expand its production capacity to meet the high demand for new treatments if approved by the FDA.
Image Credit: Getty
You read: A new ground-breaking treatment has prevented covid death by 55%